This approach combines TCR-T cell therapy and lentiviral transduction to target HBV-related recurrence in liver transplant recipients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: